The company plans to file for approval of etripamil in paroxysmal supraventricular tachycardia (PSVT) in mid-2023, with the drug having the possibility to reach sales of $1bn or more.
Milestone Pharmaceuticals, Inc. is looking at a significant potential commercial opportunity with positive results from its Phase III study of etripamil in paroxysmal supraventricular tachycardia (PSVT), given that the drug would be the first self-administered therapy for a condition that usually requires care in a hospital.
Milestone announced the results of the Phase III RAPID trial on 17 October, and the company added it plans to...
Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.
Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.
A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.
As CEO Anderson backs high prices for innovative drugs in Europe
US green light will further expand sales of the prostate cancer blockbuster.
Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.
Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.
